Cameco CCJ
Cameco is a Canadian company dedicated to the exploration, extraction, and refining of uranium, selling nuclear fuel to power plants worldwide. Cameco shows a solid balance sheet (ND/EBITDA 0.14) but extreme valuation (P/E 154.51) and severe earnings deterioration (-92.1%), placing it at a low point in the uranium cycle with regulatory and geopolitical risks.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Cameco is a Canadian company dedicated to the exploration, extraction, and refining of uranium, selling nuclear fuel to power plants worldwide. Cameco shows a solid balance sheet (ND/EBITDA 0.14) but extreme valuation (P/E 154.51) and severe earnings deterioration (-92.1%), placing it at a low point in the uranium cycle with regulatory and geopolitical risks.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.5 |
| Quality / Moat | 2.7 |
| Valuation | 0.6 |
| Growth | 0.3 |
| Dividend | 4.2 |
| Momentum | 7.0 |
| Risk & Context | 5.9 |
OVERALL SCORE: 4.1/10
Context and risks
Cameco is in the spotlight of the cyclical growth cap due to its uranium exposure, a sector with high price volatility and dependence on regulatory and geopolitical decisions. The 92% drop in earnings and 9.11% operating margin reflect the current cycle weakness, not a sustainable trend.
News considered in the analysis
- Cameco’s Westinghouse Stake Could Be Worth More Than $24.5 Billion — La posible revalorización de su participación en Westinghouse es un activo material no reflejado en los múltiplos actuales, aunque la realización del valor depende de una venta o reestructuración.
- Here's Why Cameco (CCJ) Fell More Than Broader Market — La caída relativa ya está descontada en el precio y el momentum; no aporta información nueva sobre fundamentales.
- 3 Canadian Growth Stocks With Earnings Growth Over 34% — Listículo genérico sin información específica accionable.
- Uranium Royalty (UROY) Posts Strong Q1, But One-Off Gains Complicate the Earnings Picture — Noticia sobre un competidor sin impacto directo en Cameco.
- Is the Options Market Predicting a Spike in Cameco Stock? — Ruido de mercado sin información fundamental nueva.
Verdict: Hold or avoid: valuation does not justify the cycle risk and earnings decline.
Main risk: Dependence on the uranium cycle and nuclear energy developments, combined with extreme valuation, means any delay in uranium price recovery or new reactor approvals will hit the stock hard.
Other Energy companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →